S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

PFE Pfizer Inc

25.90

0.34 (1.33%)

20 Feb 2025 - Closed

Delayed by 15 minutes

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Pfizer (NYSE:PFE)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Pfizer Charts.

Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Pfizer Charts.

Pfizer Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (1 day ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 15 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Saturday 15 February 2025 (5 days ago) • Edgar (US Regulatory)

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Friday 14 February 2025 (7 days ago) • Business Wire

ViiV Soins de santé et l'Alliance pharmaceutique pancanadienne (APP) concluent les négociations avec succès concernant APRETUDE pour la prophylaxie préexposition au VIH-1
Friday 14 February 2025 (7 days ago) • PR Newswire (Canada)

ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
Friday 14 February 2025 (7 days ago) • PR Newswire (Canada)

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Thursday 13 February 2025 (1 week ago) • Business Wire

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Tuesday 11 February 2025 (1 week ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 5 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 5 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
Tuesday 4 February 2025 (2 weeks ago) • Business Wire

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Monday 3 February 2025 (2 weeks ago) • Business Wire

More Pfizer Inc News Articles

Commonwealth Bank Of Aus...

AUD vs US Dollar

National Australia Bank

Invesco QQQ Trust Series 1

S&P ASX 300 Metals and M...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions